OncoMatch/Lung Cancer — Small Cell (SCLC)/PD-L1 (CD274)
Lung Cancer — Small Cell (SCLC)PD-L1 (CD274) Clinical Trials
PD-L1 is primarily a stratification and exploratory biomarker in SCLC rather than a practical eligibility gating marker. Front-line IO regimens (atezolizumab + carboplatin/etoposide, durvalumab + chemotherapy) are approved regardless of PD-L1 level; PD-L1 expression has not defined a reliably biomarker-selected eligible subgroup. Trials enroll largely unselected by PD-L1 and use expression level for stratification or exploratory endpoint analysis.
Top recruiting PD-L1 (CD274) Lung Cancer — Small Cell (SCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Canadian Cancer Trials Group
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
Hubei Cancer Hospital
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences